Lena Saltbæk, Pernille E Bidstrup, Randi V Karlsen, Beverley L Høeg, Trine A Horsboel, Federica Belmonte, Elisabeth A W Andersen, Vibeke Zoffmann, Anne S Friberg, Mads N Svendsen, Helle G Christensen, Vesna Glavicic, Dorte L Nielsen, Susanne O Dalton, Christoffer Johansen
PURPOSE: Follow-up after breast cancer with regular visits has failed to detect recurrences, be cost-effective, and address patient needs. METHODS: MyHealth is a phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT02949167). Patients, who recently completed primary treatment for stage I-II breast cancer, were randomly assigned in variable block sizes and stratified by age and human epidermal growth factor receptor 2 status to intervention or control follow-up...
March 18, 2024: Journal of Clinical Oncology